MedTrace Logo

Hyperinsulinemic Euglycemic Clamp Protocol

NCT01408667 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-07-10

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from the presence of hypertension, HDL cholesterol, insulin resistance, dysglycemia and visceral obesity.

Conditions

  • Metabolic Cardiovascular Syndrome

Interventions

DRUG

TRC150094

50 mg Tablets once a day

OTHER

Placebo

Tablets once daily

Sponsors & Collaborators

  • Torrent Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Erik Stroes, MD, PhD · Department of Vascular Medicine, AMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408667 on ClinicalTrials.gov